[The new anticoagulants].

Harefuah

Department of Hematology, Barzilai Medical Center, Ashkelon.

Published: May 2011

Anticoagulant therapy is based on two veteran drugs, which have been in use for over 60 years: heparin and warfarin. Due to the limitations of these agents, new parenteral anticoagulants have been introduced, mainly the low molecular weight heparins, fondaparinux and direct thrombin inhibitors. The need to develop new drugs has led to major efforts by the pharmaceutical industry and many promising anticoagulant oral agents are being tested. Ximelgatran has been withdrawn from the market after several cases of hepatotoxicity have been observed. Two oral agents, dabigatran and rivaroxaban, have recently been approved in Europe. Dabigatran inhibits thrombin, while rivaroxaban is factor X inhibitor. Other drugs include apixaban, idraparinux and are in Phase III studies.

Download full-text PDF

Source

Publication Analysis

Top Keywords

oral agents
8
[the anticoagulants]
4
anticoagulants] anticoagulant
4
anticoagulant therapy
4
therapy based
4
based veteran
4
veteran drugs
4
drugs years
4
years heparin
4
heparin warfarin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!